Evidence map›Paper›PMID 37650773›Full record

ArticleMedical physics2023

Analytical HDR prostate brachytherapy planning with automatic catheter and isotope selection.

Catherine Holly Frank, Pavitra Ramesh, Qihui Lyu, Dan Ruan, Sang-June Park, Albert J Chang, Puja S Venkat, Amar U Kishan, Ke Sheng

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical physics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Catherine Holly FrankDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California, USA.
Pavitra RameshDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California, USA.
Qihui LyuDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California, USA.
Dan RuanDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California, USA.
Sang-June ParkDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California, USA.
Albert J ChangDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California, USA.
Puja S VenkatDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California, USA.
Amar U KishanDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California, USA.
Ke ShengDepartment of Radiation Oncology, University of California Los Angeles, Los Angeles, California, USA.
University of California, Los Angeles · US

Funding

Development of a versatile robotic radiation therapy systemR44CA183390 · NCI · RADIABEAM TECHNOLOGIES, LLC · PI SHENG, KE, YONEMOTO, JAY · 2017 to 2024
$5.8M
Development of an ultra-high dose rate rotational linac for FLASH RadiotherapyR01CA255432 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AGUSTSSON, RONALD, SHENG, KE · 2021 to 2025
$3.2M
Development of A High Throughput Image-Guided IMRT System forPreclinical ResearchR01CA259008 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHENG, KE · 2021 to 2025
$2.3M
Robust IMPT with automated beam orientation and scanning spot optimizationR01CA230278 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHENG, KE · 2019 to 2023
$1.9M
NCI NIH HHS R01 CA230278NCI NIH HHS R01 CA255432NCI NIH HHS R01 CA259008NCI NIH HHS R44 CA183390NIH HHS R01CA230278NIH HHS R01CA255432NIH HHS R01CA259008NIH HHS R44CA183390
6 · The paper itself

Abstract

backgroundHigh dose rate (HDR) brachytherapy is commonly used to treat prostate cancer. Existing HDR planning systems solve the dwell time problem for predetermined catheters and a single energy source. PURPOSE: Additional degrees of freedom can be obtained by relaxing the catheters' pre-designation and introducing more source types, and may have a dosimetric benefit, particularly in improving conformality to spare the urethra. This study presents a novel analytical approach to solving the corresponding HDR planning problem.

methodsThe catheter and dual-energy source selection problem was formulated as a constrained optimization problem with a non-convex group sparsity regularization. The optimization problem was solved using the fast-iterative shrinkage-thresholding algorithm (FISTA). Two isotopes were considered. The dose rates for the HDR 4140 Ytterbium (Yb-169) source and the Elekta Iridium (Ir-192) HDR Flexisource were modeled according to the TG-43U1 formalism and benchmarked accordingly. Twenty-two retrospective HDR prostate brachytherapy patients treated with Ir-192 were considered. An Ir-192 only (IRO), Yb-169 only (YBO), and dual-source (DS) plan with optimized catheter location was created for each patient with N catheters, where N is the number of catheters used in the clinically delivered plans. The DS plans jointly optimized Yb-169 and Ir-192 dwell times. All plans and the clinical plans were normalized to deliver a 15 Gy prescription (Rx) dose to 95% of the clinical treatment volume (CTV) and evaluated for the CTV D90%, V150%, and V200%, urethra D0.1cc and D1cc, bladder V75%, and rectum V75%. Dose-volume histograms (DVHs) were generated for each structure.

resultsThe DS plans ubiquitously selected Ir-192 as the only treatment source. IRO outperformed YBO in organ at risk (OARs) OAR sparing, reducing the urethra D0.1cc and D1cc by 0.98% (

conclusionsThe proposed analytical HDR planning algorithm integrates catheter and isotope selection with dwell time optimization for varying clinical goals, including urethra sparing. The planning method can guide HDR implants and identify promising isotopes for specific HDR clinical goals, such as target conformality or OAR sparing.

Indexed as

BrachytherapyProstatic NeoplasmsCathetersHumansIridium RadioisotopesMaleProstateRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRetrospective StudiesIridium-192Iridium Radioisotopesbrachytherapy planningcatheter and isotope selectiongroup sparsity

Identifiers

PMID37650773
PMCPMC10635680
OpenAlexW4386305505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.